These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 9654593)

  • 21. Biological markers as a predictor for response and prognosis of unresectable gastric cancer patients treated with irinotecan and cisplatin.
    Nagashima F; Boku N; Ohtsu A; Yoshida S; Hasebe T; Ochiai A; Sakata Y; Saito H; Miyata Y; Hyodo I; Ando M
    Jpn J Clin Oncol; 2005 Dec; 35(12):714-9. PubMed ID: 16303791
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treosulfan in platinum-resistant ovarian cancer.
    Olesen KD; Larsen ATR; Jensen LH; Steffensen KD; Søndergaard SR
    Int J Gynecol Cancer; 2021 Jul; 31(7):1045-1051. PubMed ID: 34006568
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evidence for a dose-response effect between p53 (but not p21WAF1/Cip1) protein concentrations, survival, and responsiveness in patients with epithelial ovarian cancer treated with platinum-based chemotherapy.
    Levesque MA; Katsaros D; Massobrio M; Genta F; Yu H; Richiardi G; Fracchioli S; Durando A; Arisio R; Diamandis EP
    Clin Cancer Res; 2000 Aug; 6(8):3260-70. PubMed ID: 10955812
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expression of SGLT1, Bcl-2 and p53 in primary pancreatic cancer related to survival.
    Casneuf VF; Fonteyne P; Van Damme N; Demetter P; Pauwels P; de Hemptinne B; De Vos M; Van de Wiele C; Peeters M
    Cancer Invest; 2008 Oct; 26(8):852-9. PubMed ID: 18853313
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expression of Bcl-xL in ovarian carcinoma is associated with chemoresistance and recurrent disease.
    Williams J; Lucas PC; Griffith KA; Choi M; Fogoros S; Hu YY; Liu JR
    Gynecol Oncol; 2005 Feb; 96(2):287-95. PubMed ID: 15661210
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Survivin expression as a prognostic factor in patients with epithelial ovarian cancer or primary peritoneal cancer treated with neoadjuvant chemotherapy.
    Gąsowska-Bodnar A; Bodnar L; Dąbek A; Cichowicz M; Jerzak M; Cierniak S; Kozłowski W; Baranowski W
    Int J Gynecol Cancer; 2014 May; 24(4):687-96. PubMed ID: 24662134
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic significance of biological apoptosis factors in gastric cancer.
    Sezer C; Yildirim M; Yildiz M; Sezgin A; Donem Dilli U; Goktas S; Bulbuller N
    J BUON; 2013; 18(1):138-46. PubMed ID: 23613399
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reduced expression of BAX is associated with poor prognosis in patients with epithelial ovarian cancer: a multifactorial analysis of TP53, p21, BAX and BCL-2.
    Schuyer M; van der Burg ME; Henzen-Logmans SC; Fieret JH; Klijn JG; Look MP; Foekens JA; Stoter G; Berns EM
    Br J Cancer; 2001 Nov; 85(9):1359-67. PubMed ID: 11720475
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chemotherapy versus hormonal treatment in platinum- and paclitaxel-refractory ovarian cancer: a randomised trial of the German Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group Ovarian Cancer.
    du BA; Meier W; Lück HJ; Emon G; Moebus V; Schroeder W; Costa S; Bauknecht T; Olbricht S; Jackisch C; Richter B; Wagner U
    Ann Oncol; 2002 Feb; 13(2):251-7. PubMed ID: 11886002
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mcl-1 is an important determinant of the apoptotic response to the BH3-mimetic molecule HA14-1 in cisplatin-resistant ovarian carcinoma cells.
    Simonin K; Brotin E; Dufort S; Dutoit S; Goux D; N'diaye M; Denoyelle C; Gauduchon P; Poulain L
    Mol Cancer Ther; 2009 Nov; 8(11):3162-70. PubMed ID: 19887550
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treosulfan in the Treatment of Advanced Ovarian Cancer - Results of a German Multicenter Non-interventional Study.
    Chekerov R; Kaltenecker G; Reichert D; Göhler T; Klare P; Oskay-Özcelik G; Sauer U; Wischnik A; Vehling-Kaiser U; Becker M; Hutzschenreuter U; Ammon A; Heidrich-Lorsbach E; Sehouli J
    Anticancer Res; 2015 Dec; 35(12):6869-75. PubMed ID: 26637909
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Survival in patients with clear cell carcinoma of the ovary].
    Nakano T; Enoki K; Nakashima M; Ishikawa H; Ametani Y; Ohta S; Ohkuchi A; Satake S; Kojima Y; Funamoto H; Tateno M; Miwa A
    Gan To Kagaku Ryoho; 1998 Jan; 25(1):67-73. PubMed ID: 9464331
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo.
    Concin N; Hofstetter G; Berger A; Gehmacher A; Reimer D; Watrowski R; Tong D; Schuster E; Hefler L; Heim K; Mueller-Holzner E; Marth C; Moll UM; Zeimet AG; Zeillinger R
    Clin Cancer Res; 2005 Dec; 11(23):8372-83. PubMed ID: 16322298
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of an ATP-based chemosensitivity assay to design new combinations of high-concentration doxorubicin with other drugs for recurrent ovarian cancer.
    Di Nicolantonio F; Neale MH; Knight LA; Lamont A; Skailes GE; Osborne RJ; Allerton R; Kurbacher CM; Cree IA
    Anticancer Drugs; 2002 Jul; 13(6):625-30. PubMed ID: 12172508
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The prognostic significance of Bcl-2 and p53 expression in ovarian carcinoma.
    Herod JJ; Eliopoulos AG; Warwick J; Niedobitek G; Young LS; Kerr DJ
    Cancer Res; 1996 May; 56(9):2178-84. PubMed ID: 8616869
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunohistochemistry with apoptotic-antiapoptotic proteins (p53, p21, bax, bcl-2), c-kit, telomerase, and metallothionein as a diagnostic aid in benign, borderline, and malignant serous and mucinous ovarian tumors.
    Ozer H; Yenicesu G; Arici S; Cetin M; Tuncer E; Cetin A
    Diagn Pathol; 2012 Sep; 7():124. PubMed ID: 22995373
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic significance of HER-2, p53 and Bcl-2 in patients with epithelial ovarian cancer.
    Malamou-Mitsi V; Crikoni O; Timotheadou E; Aravantinos G; Vrettou E; Agnantis N; Fountzilas G
    Anticancer Res; 2007; 27(2):1157-65. PubMed ID: 17465257
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and Bcl-2.
    Eliopoulos AG; Kerr DJ; Herod J; Hodgkins L; Krajewski S; Reed JC; Young LS
    Oncogene; 1995 Oct; 11(7):1217-28. PubMed ID: 7478541
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adjuvant cisplatin-based chemotherapy for stage I ovarian adenocarcinoma: a preliminary report.
    Piver MS; Malfetano J; Baker TR; Lele SB; Marchetti DL
    Gynecol Oncol; 1989 Oct; 35(1):69-72. PubMed ID: 2792905
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.